Literature DB >> 15845669

An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates.

Nina A Guzzetta1, Bruce E Miller, Kathy Todd, Fania Szlam, Renee H Moore, Steven R Tosone.   

Abstract

We compared the adequacy of heparinization in neonates and older children undergoing cardiopulmonary bypass (CPB) by measuring heparin activity, thrombin formation, and thrombin activity. Ten neonates and 10 older children were administered 400 U/kg of heparin before CPB. Heparin anti-Xa activity, prothrombin fragment 1.2 (F1.2), and fibrinopeptide A (FPA) were measured at baseline, after 30 min on CPB, immediately post-CPB, and 3 and 24 h post-CPB. Heparin anti-Xa activity was significantly decreased during and immediately post-CPB in the neonatal group. F1.2 and FPA levels in neonates were significantly higher at baseline, decreased with the commencement of CPB, and increased to levels higher than those in older children after CPB. Our data show that with standard heparin doses, neonates exhibit less heparin anti-Xa activity during CPB. Higher baseline levels of F1.2 and FPA present in neonates indicate preoperative activation of their coagulation systems as compared with older children. Although F1.2 and FPA levels initially decrease with the commencement of CPB, probably representing hemodilution, the subsequent increase in these markers indicates significantly more thrombin formation and activity during and after CPB. These results raise the concern that 400 U/kg of heparin may not adequately suppress thrombin formation and activity in neonates undergoing CPB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845669     DOI: 10.1213/01.ANE.0000149590.59294.3A

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

Review 1.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

Review 2.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

3.  Perioperative Management of a Child with Hypoplastic Left Heart Syndrome of the Jehovah's Witness Faith Presenting for Hybrid Comprehensive Stage II Procedure.

Authors:  Sathappan Karuppiah; Christopher Mckee; Ashley Hodge; Mark Galantowicz; Joseph Tobias; Aymen Naguib
Journal:  J Extra Corpor Technol       Date:  2016-09

Review 4.  Anticoagulation Strategies in Pediatric Cardiopulmonary Bypass, Weight-Based vs. Concentration-Based Approaches.

Authors:  Justine Harnish; Kevin Beyer; Julie Collins
Journal:  J Extra Corpor Technol       Date:  2022-06

5.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.

Authors:  Hesham Al-Sallami; Fiona Newall; Paul Monagle; Vera Ignjatovic; Noel Cranswick; Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

6.  Use of Confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study.

Authors:  Chiara Giorni; Zaccaria Ricci; Francesca Iodice; Cristiana Garisto; Isabella Favia; Angelo Polito; Adriano Carotti; Paola Cogo
Journal:  Pediatr Cardiol       Date:  2013-07-11       Impact factor: 1.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.